Patient community and AI mentor
Belong.Life
BelongAI Dave offers patient cancer questions, information, and document sharing. Its policy also permits commercial content and secondary use of depersonalized history. The posture is Mixed, with consumer and enterprise deployments assessed separately.
Published September 8, 2026 as an AI-assisted draft. The public report separates documented facts, agency judgments and unresolved questions.
Summary judgment · 69 out of 100 toward patient-directed
BelongAI Dave cancer mentor and patient community. Enterprise private-label and clinical tools have different operators and require separate deployment descriptions.
Mixed
BelongAI Dave offers patient cancer questions, information, and document sharing. Its policy also permits commercial content and secondary use of depersonalized history. The posture is Mixed, with consumer and enterprise deployments assessed separately.
Patient agency
How this tool changes agency
Cancer information, community experience and a shareable binder can broaden patient questions. Per-answer citations, correction of mentor interpretations and moderation appeals were not verified.
Sponsor visibility, mentor source provenance, redirection and correction behavior remain unverified
Patient agency assessment
Who sets and changes the goal?
Patients can ask their own questions and choose document sharing in the described consumer workflow. Sponsor-content mechanisms create additional objectives, but actual steering of clinical recommendations was not established.
What can the patient understand, question, or do?
Cancer information, community experience and a shareable binder can broaden patient questions. Per-answer citations, correction of mentor interpretations and moderation appeals were not verified.
Can the patient evaluate the conditions of use?
The seed's general positive label needs the documented commercial and secondary-use conditions. Account deletion is not a promise to remove every depersonalized derivative.
Text findings
Conditions of use
Published controls and their limits
The seed's general positive label needs the documented commercial and secondary-use conditions. Account deletion is not a promise to remove every depersonalized derivative.
What remains unknown?
Not tested or not established
Sponsor visibility, mentor source provenance, redirection and correction behavior remain unverified
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
- https://belong.life/belong-ai-cancer-mentor-app/
- https://belong.life/privacy-policy/
- https://belong.life/
Source-specific findings and retrieval limitations are recorded in the full report.
Review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Sponsor visibility, mentor source provenance, redirection and correction behavior remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
AI-assisted draft · Moderate for public product and policy claims, limited for actual patient experience (AI-assisted draft)